Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Systemic Lupus Erythematosus (SLE-BRAVE I)
NCT03616912Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response at Week 52. Started Aug 2018; status: terminated.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03616912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616912.